Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityActive in the last 2 years

Stefano Cascinu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-2215-0731; OpenAlex author ID A5042028913, A5112860438. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 12)
Trials
0
Grants
0
Labs led
2
Collaborators
124
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 7 papers · 2016: 3 papers · 2017: 5 papers · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 7 papers · 2022: 1 paper · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers

Papers 39

  1. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  2. Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life. Co-author DOI 10.1016/j.dld.2024.06.025↗
  3. Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ctro.2024.100778↗
  4. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.dld.2023.07.033↗
  5. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  6. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA… Co-author DOI 10.1007/s00280-023-04585-w↗
  7. The Role of Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer: A Network Meta-Analysis. Co-author DOI 10.1007/s12029-023-00923-6↗
  8. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  9. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1016/j.ctrv.2022.102357↗
  10. Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Co-author DOI 10.1007/s00280-020-04190-1↗
  11. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants. Co-author DOI 10.1016/j.ctrv.2021.102262↗
  12. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  13. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. Co-author DOI 10.1016/j.esmoop.2020.100032↗
  14. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  15. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Co-author DOI 10.1177/0300891620976945↗
  16. Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Co-author DOI 10.3390/cancers13194938↗
  17. Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-37433-6↗
  18. Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Co-author DOI 10.3390/cancers11020193↗
  19. An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the… Co-author DOI 10.1080/14737167.2018.1464394↗
  20. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  21. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.critrevonc.2017.01.015↗
  22. Borderline resectable pancreatic cancer: More than an anatomical concept. Last author DOI 10.1016/j.dld.2016.11.010↗
  23. Emerging antibodies for the treatment of pancreatic cancer. Last author DOI 10.1080/14728214.2017.1293649↗
  24. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. Co-author DOI 10.1186/s12885-017-3131-x↗
  25. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.critrevonc.2015.11.016↗
  26. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Co-author DOI 10.1016/j.ejso.2016.06.398↗
  27. Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Co-author DOI 10.18632/oncotarget.10765↗
  28. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. First author DOI 10.1016/j.pan.2014.10.001↗
  29. [Treatment of pancreatic cancer. Actuality and perspective]. Last author DOI 10.1701/1868.20404↗
  30. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Co-author DOI 10.18632/oncotarget.4492↗
  31. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Last author DOI 10.18632/oncotarget.5197↗
  32. Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Last author DOI 10.2217/fon.15.27↗
  33. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Last author DOI 10.2217/fon.15.98↗
  34. HER family receptor expression and prognosis in pancreatic cancer. Last author DOI 10.5301/jbm.5000157↗
  35. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Co-author DOI 10.1016/j.dld.2013.09.020↗
  36. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Last author DOI 10.1155/2014/183852↗
  37. Cetuximab: still an option in the treatment of pancreatic cancer? Last author DOI 10.1517/14712598.2013.786697↗
  38. Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches? Co-author DOI 10.3978/j.issn.2304-3865.2013.07.01↗
  39. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Co-author DOI 10.1007/s00280-012-1875-1↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 20 shared papers, 2015–2025 · strength 2.43
  2. Giulia Orsi · 15 shared papers, 2019–2025 · strength 2.14
  3. Marina Macchini · 13 shared papers, 2021–2025 · strength 1.97
  4. Umberto Peretti · 11 shared papers, 2021–2025 · strength 1.66
  5. Massimo Falconi · 10 shared papers, 2015–2024 · strength 1.03
  6. Guido Giordano · 7 shared papers, 2021–2025 · strength 0.95
  7. Alessandro Bittoni · 13 shared papers, 2014–2025 · strength 0.89
  8. Giampaolo Tortora · 7 shared papers, 2018–2025 · strength 0.83
  9. Ilario Giovanni Rapposelli · 6 shared papers, 2021–2025 · strength 0.80
  10. Michèle Milella · 6 shared papers, 2018–2025 · strength 0.68
  11. Lisa Salvatore · 5 shared papers, 2021–2025 · strength 0.66
  12. Anna Maria Militello · 5 shared papers, 2021–2023 · strength 0.65
  13. Letizia Procaccio · 4 shared papers, 2023–2025 · strength 0.62
  14. Monica Niger · 5 shared papers, 2021–2025 · strength 0.60
  15. Kalliopi Andrikou · 10 shared papers, 2013–2021 · strength 0.57
  16. Mario Scartozzi · 6 shared papers, 2015–2025 · strength 0.56
  17. Elisa Giommoni · 4 shared papers, 2021–2025 · strength 0.51
  18. Silvia Bozzarelli · 4 shared papers, 2021–2025 · strength 0.51
  19. Luca Faloppi · 6 shared papers, 2013–2025 · strength 0.47
  20. Andrea Spallanzani · 4 shared papers, 2021–2025 · strength 0.47
  21. Maria Grazia Rodriquenz · 4 shared papers, 2021–2025 · strength 0.46
  22. Mariacristina Di Marco · 4 shared papers, 2021–2025 · strength 0.46
  23. Stefania Mosconi · 5 shared papers, 2014–2025 · strength 0.42
  24. Giulio Belfiori · 3 shared papers, 2021–2024 · strength 0.40
  25. Domenico Tamburrino · 3 shared papers, 2021–2024 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.